Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Cutaneous Lupus and Dermatomyositis: Management Pearls and Pitfalls for the General Dermatologist
Description
The presentation focuses on cutaneous lupus and dermatomyositis, specifically addressing the challenges in diagnosis and management for dermatologists. It begins with cases of patients exhibiting discoid lupus, noting distinct features suggestive of lupus paniculitis, which affects fat lobules and can mimic other conditions like erythema nodosum. The speaker explains the clinical presentation of lupus paniculitis, emphasizing the need for a high index of suspicion when diagnosing variants like lupus mastitis, particularly in patients with inconclusive breast biopsies. Detailed discussions of treatment options follow, advocating for aggressive management of lupus paniculitis to prevent disfigurement and highlighting the importance of targeting the inflammatory stage with therapies like corticosteroids. Following stabilization, treatment options for contour restoration, such as autologous fat transfer or fillers, are also discussed. The talk transitions to Raynaud's phenomenon, prevalent in lupus and myositis conditions, detailing its management through lifestyle changes, pharmacological treatments like calcium channel blockers and PDE5 inhibitors, and innovative therapies such as botulinum toxin injections. The speaker underscores the significance of treating Raynaud's effectively to alleviate patient suffering and prevent severe complications.
View moreConclusions
- Lupus panniculitis consists of inflammation in the fat, predominantly located in fatty areas such as the cheeks and upper arms.
- There are two main types of lupus panniculitis: lupus panniculitis (without associated discoid lupus) and lupus profundus (with associated discoid lupus).
- It is crucial to diagnose lupus paniculitis early, as those without discoid lupus often experience diagnostic delays.
- Patients with lupus panniculitis may experience significant contour changes and atrophy due to fat lobule destruction.
- Treatment typically involves anti-inflammatory therapies such as prednisone, methotrexate, hydroxychloroquine, and mycophenolate mofetil, but monotherapy is often insufficient.
- For recontouring or adding volume after lupus panniculitis, options include autologous fat transfer or dermal fillers, to be used only when the disease is quiescent.
- Lupus mastitis may mimic breast cancer; healthcare providers should maintain a high index of suspicion in patients with lupus panniculitis presenting with abnormal mammograms.
- In cases where lupus panniculitis presents atypically or is unresponsive to treatment, there is a risk of misdiagnosis with conditions like subcutaneous panniculitis-like T-cell lymphoma (SPTCL).
- Raynaud’s phenomenon can occur in lupus patients, with necessary treatments including behavioral modifications and medications like calcium channel blockers and PDE-5 inhibitors such as sildenafil.
- Access to medications like sildenafil can be challenging, and options to reduce costs, including GoodRx and Cost Plus, are valuable resources.
- Carducci M, et al. J Eur Acad Dermatol Venereol. 2005;19(2):260-262.
- Dandinoglu T, et al. Orthop Muscul Syst. 2014;3(1):13-15.
- Fernández-Torres R, et al. J Am Acad Dermatol. 2009;60(6):1074-1076.
- Rosa M, et al. Ann Diagn Pathol. 2013;17(2):230-233.
- Rangel LK, et al. JAMA Dermatology. November 2020;156(11).
- Khan F. Scott Med J. 1999;44(1):4-6.
- Lemaitre F. Arch Med Sci. 2015;11(2):419-26.
- Hachulla E, et al. Ann Rheum Dis. 2016;75:1009-1015.
- Cochrane Database of Systematic Reviews. 2017, Issue 12. Art. No .: CD000467.
- Smith L, et al. JAAD. 2013;69(5):834-835.
- Bello RJ, et al. Arthritis Rheumatol. 2017;69(8):1661-1669.
- Barry KK, et al. Pediatr Dermatol. 2023;40(3):587-589.